WO2004047916A1 - イオントフォレーシス装置 - Google Patents
イオントフォレーシス装置 Download PDFInfo
- Publication number
- WO2004047916A1 WO2004047916A1 PCT/JP2003/015105 JP0315105W WO2004047916A1 WO 2004047916 A1 WO2004047916 A1 WO 2004047916A1 JP 0315105 W JP0315105 W JP 0315105W WO 2004047916 A1 WO2004047916 A1 WO 2004047916A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ion exchange
- exchange membrane
- ion
- drug
- porous film
- Prior art date
Links
- 239000003014 ion exchange membrane Substances 0.000 claims abstract description 119
- 229940079593 drug Drugs 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 98
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 24
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 24
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000001962 electrophoresis Methods 0.000 claims abstract description 7
- 239000011800 void material Substances 0.000 claims abstract description 5
- 239000011148 porous material Substances 0.000 claims description 10
- 229920005992 thermoplastic resin Polymers 0.000 claims description 6
- 239000012466 permeate Substances 0.000 abstract description 6
- 238000001647 drug administration Methods 0.000 abstract description 4
- 239000000178 monomer Substances 0.000 description 51
- 238000005342 ion exchange Methods 0.000 description 32
- 150000002500 ions Chemical class 0.000 description 29
- 239000000203 mixture Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000463 material Substances 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 16
- -1 B12 Natural products 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 239000002585 base Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000005341 cation exchange Methods 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 8
- 239000002759 woven fabric Substances 0.000 description 8
- 239000003011 anion exchange membrane Substances 0.000 description 7
- 230000003746 surface roughness Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 238000005349 anion exchange Methods 0.000 description 6
- 239000003505 polymerization initiator Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008151 electrolyte solution Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical class C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 description 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 2
- IWTYTFSSTWXZFU-UHFFFAOYSA-N 3-chloroprop-1-enylbenzene Chemical compound ClCC=CC1=CC=CC=C1 IWTYTFSSTWXZFU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229960004931 histamine dihydrochloride Drugs 0.000 description 2
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920005672 polyolefin resin Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- FVQMJJQUGGVLEP-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOOC(C)(C)C FVQMJJQUGGVLEP-UHFFFAOYSA-N 0.000 description 1
- WVAFEFUPWRPQSY-UHFFFAOYSA-N 1,2,3-tris(ethenyl)benzene Chemical compound C=CC1=CC=CC(C=C)=C1C=C WVAFEFUPWRPQSY-UHFFFAOYSA-N 0.000 description 1
- AYMDJPGTQFHDSA-UHFFFAOYSA-N 1-(2-ethenoxyethoxy)-2-ethoxyethane Chemical compound CCOCCOCCOC=C AYMDJPGTQFHDSA-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- OEVVKKAVYQFQNV-UHFFFAOYSA-N 1-ethenyl-2,4-dimethylbenzene Chemical compound CC1=CC=C(C=C)C(C)=C1 OEVVKKAVYQFQNV-UHFFFAOYSA-N 0.000 description 1
- JZHGRUMIRATHIU-UHFFFAOYSA-N 1-ethenyl-3-methylbenzene Chemical compound CC1=CC=CC(C=C)=C1 JZHGRUMIRATHIU-UHFFFAOYSA-N 0.000 description 1
- IYSVFZBXZVPIFA-UHFFFAOYSA-N 1-ethenyl-4-(4-ethenylphenyl)benzene Chemical group C1=CC(C=C)=CC=C1C1=CC=C(C=C)C=C1 IYSVFZBXZVPIFA-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- LQJPFRZLZSLIIO-UHFFFAOYSA-N 2,11-dimethyldodeca-2,10-dienediamide Chemical compound NC(=O)C(C)=CCCCCCCC=C(C)C(N)=O LQJPFRZLZSLIIO-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WNGZFTDRTBIMQZ-UHFFFAOYSA-N 2-benzyl-n,n-diethylbut-3-en-1-amine Chemical compound CCN(CC)CC(C=C)CC1=CC=CC=C1 WNGZFTDRTBIMQZ-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical compound CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000201776 Steno Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- VNGOYPQMJFJDLV-UHFFFAOYSA-N dimethyl benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC=CC(C(=O)OC)=C1 VNGOYPQMJFJDLV-UHFFFAOYSA-N 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003411 electrode reaction Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000011532 electronic conductor Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- KETWBQOXTBGBBN-UHFFFAOYSA-N hex-1-enylbenzene Chemical compound CCCCC=CC1=CC=CC=C1 KETWBQOXTBGBBN-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- WFIJWRVKQZECDG-UHFFFAOYSA-N methane 2-methylprop-2-enoic acid Chemical compound C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C WFIJWRVKQZECDG-UHFFFAOYSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- XCWHOBZHKZPWSB-UHFFFAOYSA-N n,n-dimethyl-1-phenylbut-3-en-2-amine Chemical compound CN(C)C(C=C)CC1=CC=CC=C1 XCWHOBZHKZPWSB-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- SRSFOMHQIATOFV-UHFFFAOYSA-N octanoyl octaneperoxoate Chemical compound CCCCCCCC(=O)OOC(=O)CCCCCCC SRSFOMHQIATOFV-UHFFFAOYSA-N 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical group [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 239000011342 resin composition Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical group FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0444—Membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
Definitions
- the present invention relates to an iontophoresis device for performing iontophoresis (ion permeation therapy) in which an ionic drug useful for a living body is penetrated into the living body using electrophoresis.
- the present invention relates to an iontophoresis device using an ion exchange membrane and an ion exchange membrane used in the device.
- Iontophoresis which uses an electrophoresis to penetrate a useful ionic drug into the living body using electrophoresis, is also called iontophoresis, iontophoresis, etc., and administers a desired amount of drug to the desired affected area without pain It is widely known as a way to do it.
- a drug layer impregnated with an ionic drug is placed on a living body, a working electrode is arranged on the opposite side of the living body with the drug layer interposed, and a counter electrode is placed on the living body away from the drug layer.
- the ionic drug penetrates the living body by passing current between the working electrode and the counter electrode by the power supply.
- This method aims at allowing only an ionic drug to penetrate into a living body through a biological interface such as skin or mucous membrane.
- the ionic drug does not always pass through the biological interface.
- sodium cation, potassium cation, chloride anion and the like permeate into the drug layer from the living body.
- ionic drugs that are useful for living organisms have lower mobility than ions that exist in living organisms as described above. Efficiency) was low. Further, in such iontophoresis, since the drug comes into direct contact with the electrode, not only the drug is consumed by the reaction at the electrode, but also there is a possibility that a compound that adversely affects the living body may be generated. Furthermore, since drugs are usually used in the form of an aqueous solution, the electrolysis of water proceeds at the working electrode and the counter electrode, and the pH of the aqueous drug solution changes due to H + ions and OH- ions generated by this. Cause inflammation in There was also.
- Patent Documents 1 to 4 a new method of iontophoresis in which an ion exchange membrane is placed on a biological interface and drug ions penetrate into a living body through the ion exchange membrane has been proposed (for example, Patent Documents 1 to 4). 4).
- Patent Document 1 Japanese Patent Application Laid-Open No. 3-974771
- Patent Literature 2 Japanese Patent Publication No. Hei 3-5504343
- Patent Document 3 Japanese Patent Application Laid-Open No. Hei 4-29 7 27 7
- Patent Literature 4 Japanese Patent Application Laid-Open No. 2000-229129
- an ion exchange membrane disposed on a biological interface is formed by a method in which a target drug ion is formed. Only ions of the same sign are transmitted. For this reason, ions having the opposite sign to the target drug can be prevented from seeping out of the living body, and a higher dose of the drug can be obtained as compared with the case where no ion exchange membrane is provided.
- ion exchange membranes using a commercially available woven fabric used for salt production and dialysis of food compounds as a reinforcing material (substrate) are used.
- a battery such as a button-type battery is usually used as a power source, so that the voltage value is more constant (constant voltage) than when the current value is constant (constant current).
- the dose of the drug is usually used as a power source, so that the voltage value is more constant (constant voltage) than when the current value is constant (constant current).
- drug administration by iontophoresis is performed over a relatively long period of time, unlike injection and other methods. It would be desirable for the patient to be able to perform a variety of movements and actions while wearing the device.
- the dose of the drug is not sufficient. I could not say that there was a need to further increase the dosage.
- the skin portion on which the iontophoresis device is worn expands and contracts accordingly. Therefore, the ion exchange membrane used in the iontophoresis device needs to have a strength that will not be destroyed by the stress generated by such expansion and contraction or bending.
- the thicker the film the higher the strength.
- the flexibility also decreases, resulting in poor followability to expansion and contraction and bending. Therefore, if a thicker ion-exchange membrane is used with emphasis on strength, the risk of the iontophoresis device being attached coming off or falling off the skin increases. there were.
- Another object of the present invention is to provide an iontophoresis device which can be used as a portable device which is hardly broken or detached even if it is hard to be detached.
- An object of the present invention is to provide an ion-exchange membrane used for the above.
- the present inventors have conducted various studies in order to solve the above problems. As a result, they found that the use of an ion-exchange membrane using a porous film as a base material significantly increased the drug dose under constant voltage conditions. Furthermore, it has been found that an ion exchange membrane using such a porous film as a base material is much thinner and more flexible than conventional ion exchange membranes using a woven fabric, and has excellent strength. The present invention has been completed.
- a working electrode a working electrode structure provided with a drug-containing portion and an ion exchange membrane
- a counter electrode structure provided with the working electrode and a counter electrode
- Consists of a power supply unit electrically connected to the working electrode structure and the counter electrode structure.
- the ionic drug contained in the drug-containing part is subjected to electrophoresis through an ion-exchange membrane.
- an iontophoresis device to penetrate the living body
- An iontophoresis device wherein the ion exchange membrane has a structure in which a void portion of a porous film is filled with an ion exchange resin.
- a working electrode structure for iontophoresis in which an electrode, an ionic drug-containing layer, and an ion-exchange membrane are arranged in this order, wherein the ion-exchange membrane is a void of a porous film.
- a working electrode structure for iontophoresis characterized in that the working electrode structure has a structure in which a portion is filled with an ion exchange resin.
- FIG. 1 is a schematic diagram showing a typical configuration of an iontophoresis device of the present invention.
- FIG. 2 is a schematic view of an apparatus used for measuring a drug permeation amount in Examples.
- FIG. 3 is a schematic cross-sectional view of a portable iontophoresis device in which all the components are incorporated into one exterior material.
- BEST MODE FOR CARRYING OUT THE INVENTION The iontophoresis device of the present invention is used for administering an ionic drug to a living body using electrophoresis. It is characterized by using an exchange membrane, and an ionic drug is administered into a living body through such an ion exchange membrane.
- the iontophoresis device includes a working electrode structure 1, a counter electrode structure 2, and a power supply unit 3 electrically connected to these structures. (Working electrode structure 1)
- the working electrode structure 1 includes an electrode (working electrode) 4 serving as a working electrode, a drug containing portion 5 containing an ionic drug, and an ion exchange membrane 6 based on a porous film.
- This ion exchange membrane 6 selectively allows ions having the same polarity as the medicinal ions of the ionic drug to be administered to permeate.
- the working electrode 4 the drug-containing portion 5, and the ion exchange membrane 6 are arranged in this order. Normally, these members are stacked in a single exterior material (not shown) to form the working electrode structure 1, and the ion exchange membrane 6 is arranged so as to be positioned on the biological interface (skin). Used.
- an ion exchange membrane 8 may be further included between the electrode and the drug-containing layer in order to prevent the decomposition of the drug to be administered and to prevent the pH of the drug-containing portion 5 from changing due to the electrode reaction. It is preferable that the membrane 8 selectively permeates ions of the opposite polarity to the medicinal ions.
- a sheet or the like through which ions formed of an ion-conductive gel, a porous film, a woven cloth, or the like can pass can be provided between the ion exchange membrane 6 and the biological interface.
- These gels and sheets can have a structure integrated with the working electrode structure 1, and can be sandwiched between the living body interface and the gel only when used.
- Film ⁇ cloth can also be arranged.
- an electrode used in a normal electrochemical process can be used without any limitation.
- examples thereof include electrodes made of electronic conductors such as gold, platinum, silver, copper, nickel, zinc, and carbon, semiconductor electrodes, and self-sacrifice electrodes such as silver and silver chloride. These may be used alone or in combination. Can be used. Preferably, gold, platinum, silver, carbon and the like are mentioned.
- these electrodes those formed into a paper-like material obtained by laminating plates, sheets, meshes, and fibers in an irregular shape can be used as they are. It can be used by being provided by vapor deposition.
- ordinary iontophoresis Can be used without any limitation.
- a solution obtained by dissolving an ionic drug in a solvent such as water or ethanol, a gel obtained by mixing the solution with polyvinyl alcohol, polyvinylpyrrolidone, or the like, or impregnating the solution with a porous film, gauze, or the like Those that have been used can be used.
- the ionic drug used in the drug-containing portion 5 is not particularly limited, and is composed of a positive ion and a negative ion. When the positive ion or the negative ion enters the living body, The substance is not particularly limited as long as it has a pharmacological effect.
- ionic drugs examples include anionic agents such as proforce hydrochloride, lidocaine hydrochloride, and dibuforce hydrochloride, and anti-cancer drugs such as mitomycin and bleomycin hydrochloride.
- Tumor agents analgesics such as morphine hydrochloride, steroids such as medroxyprogesterone acetate, histamine, insulin, etc.
- ionic drugs exerted by negative ions include vitamin B2 and vitamin Examples include vitamins such as B12, vitamin C, vitamin E, and folic acid; anti-inflammatory agents such as aspirin and ibuprofen; corticosteroids such as dexamethasone-based water-soluble preparations; and antibiotics such as benzyl penicillin potassium.
- Single ion exchange membrane 6 Single ion exchange membrane 6—
- the ion exchange membrane 6 having a porous film as a base material is such that an ion exchange resin having a cation exchange function or a god ion exchange function is filled in part or all of the voids of the porous film. It is.
- the ion-exchange resin may be a fluorine-based ion-exchange resin in which an ion-exchange group is introduced into a perfluorocarbon skeleton, or a so-called hydrocarbon-based ion-exchange resin having a non-fluorinated resin as a skeleton.
- a hydrocarbon-based ion-exchange resin for simplicity of the production process.
- the filling rate of the ion exchange resin in the ion exchange membrane 6 is related to the porosity of the porous film described later, it is generally 5 to 95% by weight.
- the content is preferably 10 to 90% by weight, and particularly preferably 2 to 90% by weight. 0-6 0 weight 0/0.
- the ion exchange group present in the ion exchange resin is not particularly limited as long as it is a functional group that generates a group having a negative or positive charge in an aqueous solution.
- a functional group that can be an ion exchange group include a cation exchange group such as a sulfonate group, a carboxylate group, and a phosphonate group.
- These acid groups may be present as free acids or in the form of salts.
- the counter cation in the case of a salt include an alkali metal cation such as a sodium ion and a potassium ion, and an ammonium ion.
- sulfonic acid groups which are generally strongly acidic groups
- anion exchange group examples include “! To tertiary amino group, quaternary ammonium group, pyridyl group, imidazole group, quaternary pyridinium group, and quaternary imidazolium group.
- anion examples include a halogen ion such as a chloride ion and a hydroxy ion, etc.
- a quaternary ammonium group and a quaternary pyridinium group which are generally strong basic groups, are generally used. It is preferably used.
- such an ion exchange resin is a cross-linking type in that it is excellent in strength and also excellent in stability against various solvents.
- the most characteristic feature of the ion-exchange membrane 6 used in the present invention is that the above-mentioned ion-exchange resin is formed in a film shape using a porous film as a base material.
- a conventional ion-exchange membrane using a woven fabric as the substrate does not have both sufficient strength and flexibility, and further has a low drug administration efficiency.
- a cast-type ion exchange membrane formed without using a substrate cannot satisfy both sufficient strength and flexibility, and such a cast-type ion exchange membrane cannot be used.
- a solvent or the like contained in the drug-containing layer dissolves and re-swells, so that a practically usable iontophoresis device cannot be obtained.
- the porous film used as the base material of the ion exchange membrane a film having a large number of pores communicating between the front and back or a sheet-like film is used without particular limitation.
- the resin is preferably made of a thermoplastic resin.
- thermoplastic resins that make up the porous film include ethylene, propylene, and 1 Polyolefins such as butene, 1-pentene, 1-hexene, 3-methyl-1-butene, 4-methyl-11-pentene, 5-methyl-11-heptene, etc.
- Resins polyvinyl chloride, polyvinyl chloride resins such as polyvinyl chloride, vinyl chloride-vinyl acetate copolymer, vinyl chloride-vinylidene chloride copolymer, vinyl chloride-olefin copolymer: polytetrafluoroethylene, polychlorinated trifluorethylene Fluorinated resins such as poly (vinylidene fluoride), tetrafluoroethylene-hexafluoropropylene copolymer, tetrafluoroethylene-perfluoroalkylvinyl ether copolymer, and tetrafluoroethylene-ethylene copolymer
- Polyamide resins such as nylon 6 and nylon 66: limited to those made of polyimide resin, etc.
- polystyrene resin Although it is often used, it is preferable to use a polyolefin resin because of its excellent mechanical strength, flexibility, chemical stability, and chemical resistance, and good compatibility with ion exchange resins.
- polyethylene and polypropylene are particularly preferred, and polyethylene is most preferred.
- the properties of the porous film made of the thermoplastic resin are not particularly limited, but the average pore diameter of the pores is preferably 0. 005 to 5.0 im, more preferably 0.01 to 2.0 m, and most preferably 0.02 to 0.2 m.
- the average pore diameter means an average pore diameter measured according to the bubble point method (JIS K 3832-1990).
- the porosity of the porous film is preferably 20-95 ⁇ 1 ⁇ 2, more preferably 30-90%, and most preferably 30-60%.
- the thickness of the porous film is preferably 5 to 140 m, more preferably 10 to 120 m, most preferably 10 to 120 m so that the ion exchange membrane has a thickness as described below. Or 15 to 55 / m.
- the thickness of the ion-exchange membrane manufactured by the manufacturing method described later is about the thickness of the porous film used as the base material plus about 0 to 20 m.
- Such a porous film can be obtained by a method described in JP-A-9-1221964, JP-A-2002-338721, or the like. Specifically, an organic liquid is mixed with a thermoplastic resin to form a sheet or film, and then the organic liquid is extracted with a solvent, or an inorganic filler is added to the thermoplastic resin. It can be obtained by stretching a sheet made of a resin composition filled with colorant or organic filler. It can also be obtained as a commercial product (eg, Asahi Kasei "Hipore”, Ube Industries, "Yupore”, Tonen Tapyrus “Cetella J,” Todenko “Exepol”, Mitsui Chemicals "Highlet”, etc.).
- the amount of the ion exchange groups is 0.1 to 6.Ommol Zg, particularly 0.3 to 4.Ommo in terms of ion exchange capacity.
- it is of I Zg.
- the higher the ion exchange capacity the larger the drug dose at a constant voltage where the electrical resistance of the ion exchange membrane is low.
- the ion exchange capacity exceeds 4. Ommo Ig, production becomes difficult. If it exceeds 6. Ommo I Zg, production is practically impossible.
- the ion exchange membrane 6 preferably has a water content of 5% or more, preferably 10 ⁇ 1 or more, so that the electric resistance does not increase by drying. Generally, the water content is maintained at about 5 to 90%. In order to obtain a water content in such a range, it can be controlled by the type of ion exchange group, ion exchange capacity, degree of crosslinking, and the like. Further, in order to obtain a high dose of the target drug, the fixed ion concentration of the ion exchange membrane 6 is preferably 6.0 to 15. Ommo IZg—water.
- the thickness of the ion exchange membrane 6 is preferably 5 to 150 // m, more preferably 10 to 130 ⁇ m, and particularly preferably 15 to 60 jUm. The thicker the ion exchange membrane 6 is, the higher the physical strength is, while the thinner the ion exchange membrane 6 is, the better the followability to the living body surface and the lower the electrical resistance of the ion exchange membrane 6 is.
- the strength of the ion exchange membrane 6 is preferably not less than 0.2 MPa in burst strength, particularly preferably not less than 0.2 MPa, and soft is, 1 5 cm 3 Bruno 1 00 following Clark stiffness, in particular 1 0 cm 3 Z l 00 hereinafter, and most preferably 5 cm 3/1 00 in which the good or less.
- the ten-point average surface roughness R z (JIS B 0601-1994) of the ion exchange membrane 6 is preferably 1 Oim or less, particularly preferably 5 m or less. Has such a smooth surface, strength and flexibility An ion exchange membrane 6 excellent in both is obtained only by using a porous film as a base material, and cannot be obtained using a conventional woven fabric or the like as a base material.
- the method for producing the ion-exchange membrane 6 used in the present invention is not particularly limited as long as the porous film described above is used as a substrate, but from the viewpoint that a high-performance membrane can be efficiently produced, the following method is used. It is particularly preferable to produce by the production method described above. That is, a monomer composition comprising a monomer having a functional group into which an ion exchange group can be introduced, a crosslinkable monomer, and a polymerization initiator is impregnated into the pores of the porous film, A method of polymerizing a body composition and introducing a cation exchange group or an anion exchange group into the polymer.
- hydrocarbon monomers having a functional group into which a cation exchange group can be introduced include styrene, Q? -Methylstyrene, 3-methylstyrene, 4-methylstyrene, 2,4-dimethylstyrene, p-tert- Examples thereof include aromatic vinyl compounds such as butylstyrene, styrene monohalide, and vinylnaphthalene, and one or more of these can be used.
- examples of monomers having a functional group into which an anion exchange group can be introduced include styrene, vinyltoluene, chloromethylstyrene, vinylpyridine, vinylimidazole, -methylstyrene, and vinylnaphthalene.
- the crosslinkable monomer is not particularly limited, but examples thereof include polyfunctional vinyl compounds such as divinylbenzenes, divinylsulfone, butadiene, chloroprene, divinylbiphenyl, and trivinylbenzene, and trimethylol.
- Polyfunctional methacrylic acid derivatives such as methane trimethacrylate, methylenebisacrylamide, and hexamethylene dimethacrylamide are used.
- hydrocarbon-based monomers and plasticizers copolymerizable with the above-mentioned monomers and crosslinkable monomers may be added as necessary.
- examples of such other monomers include acrylonitrile, acrolein, and methyl vinyl ketone.
- the plasticizer include dibutyl phthalate, octyl phthalate, dimethyl isophthalate, dibutyl adipate, triethyl citrate, acetyl triptyl citrate, dibutyl sebacate, and dibenzyl ether.
- polymerization initiator a conventionally known one is used without any particular limitation.
- polymerization initiators include octanoyl peroxide, lauroyl peroxide, t-butyl peroxy-2-ethylhexanoate, benzoyl peroxide, t-butyl peroxyisobutyrate, Organic peroxides such as t-butyl benzoyl laurate, t-hexyl oxy benzoate, and di-t-butyl peroxide are used.
- the crosslinkable monomer is preferably 0.1 to 50 parts by mass with respect to 100 parts by mass of a monomer having a functional group into which an ion exchange group can be introduced. It is preferable that the monomer is blended in an amount of 1 to 40 parts by mass, and the other monomer copolymerizable with these monomers is preferably used in an amount of 0 to 100 parts by mass.
- the crosslinkable monomer the larger the amount of the crosslinkable monomer, the better the strength of the obtained ion exchange membrane. If the amount is too large, however, the flexibility is reduced, and However, the electric resistance of the ion exchange membrane tends to increase.
- the polymerization initiator is used in an amount of 0.1 to 20 parts by mass, preferably 100 parts by mass of the total of the monomer having a functional group into which an ion exchange group can be introduced and the crosslinkable monomer. It is preferable to add 0.5 to 10 parts by mass.
- a monomer composition comprising a monomer having a functional group into which such an ion exchange group can be introduced, a crosslinkable monomer, a polymerization initiator and other compounding components is added to the above-mentioned porous film. It may be filled and then polymerized.
- the method for filling the monomer composition into the porous film is not particularly limited.
- the monomer composition may be applied to the porous film, sprayed, or the porous film may be filled with the monomer composition. It can be suitably performed by immersing in an object.
- the above monomer composition is applied, for example, the two are contacted under reduced pressure so that the voids of the porous film are filled with the monomer composition well, or a pressure treatment is performed after the contact.
- a method in which the temperature is raised from room temperature while pressurizing a film of polyester or the like which is smooth is preferably employed.
- the polymerization conditions may be appropriately determined according to the type of the polymerization initiator used, the composition of the monomer composition, and the like. Generally, the state of heating to about 80 to 120 ° C. It may be held for about a minute to 10 hours.
- the polymer filled and polymerized in the porous film is subjected to a known ion exchange group introduction treatment to obtain an ion exchange membrane.
- a known method may be appropriately selected and adopted as a method for introducing an ion-exchange group.
- treatments such as sulfonation, chlorosulfonation, phosphonidation, and hydrolysis may be performed.
- a treatment such as amination or alkylation may be performed.
- the ion exchange membrane used in the present invention may be produced by a known ion exchange membrane production method other than the above method without any problem.
- styrene sulfonic acid vinyl sulfonic acid, vinyl monohalogen sulfonic acid, etc.
- Sulfonic acid monomers carboxylic acid monomers such as methacrylic acid, acrylic acid, and maleic anhydride; phosphonic acid monomers such as vinylphosphoric acid; Hydrogen monomers, amine monomers such as vinylbenzyltrimethylamine, vinylbenzyltriethylamine, and trimethylaminoethylmethacrylate; nitrogen-containing heterocyclic monomers such as vinylpyridine and vinylimidazole, and salts thereof And a monomer having an anion exchange group such as an ester and a crosslinkable monomer, And using a monomer composition consisting of other components, it is possible to also porous film to the charge brought after filling, to obtain even cowpea to polymerization.
- carboxylic acid monomers such as methacrylic acid, acrylic acid, and maleic anhydride
- phosphonic acid monomers such as vinylphosphoric acid
- Hydrogen monomers amine monomers such as vinylbenzyltrimethylamine, vinylbenzyltriethylamine, and trimethylamino
- an ion exchange resin soluble in a solvent or a resin having a functional group capable of introducing an ion exchange group is mixed with a solvent to form a solution or paste. It is also possible to adopt a method of obtaining a liquid composition, impregnating it with a porous film, and then removing the solvent. When using an ion exchange resin, remove the solvent. By the removal, the ion exchange membrane can be used as it is, or when a resin having a functional group capable of introducing an ion exchange group is used, the ion exchange group may be introduced by a known method after removing the solvent. .
- the counter electrode structure 2 has an electrode (counter electrode) 4 ′ that is a counter electrode of the working electrode 4 in the working electrode structure 1, and is used for a portion including the electrode that is the counter electrode in a normal iontophoresis device.
- the structure is not restricted at all. That is, the counter electrode structure 2 may be the electrode (counter electrode 4 ′) itself, or the electrode (counter electrode 4 ′) is arranged on a sheet made of ion-conductive gel, porous film or woven fabric.
- the structure may be an ion exchange membrane based on a porous film or a structure in which an electrode (counter electrode 4 ') is arranged on another ion exchange membrane.
- a counter electrode 4 ′, an electrolyte containing portion 9 containing an ionic electrolyte, and an ion exchange membrane 10 are laminated in this order, and the ion exchange membrane 10 is placed on a biological interface. It is preferable that the structure is arranged at the center.
- the ion exchange membrane 10 may be an ion exchange membrane having the above-described porous film as a base material, or may be another ion exchange membrane.
- the ion exchange membrane 10 may be any of those which selectively allow ions of the same polarity or opposite polarity as the medicinal ions of the target drug, but preferably, the target drug has a counter electrode structure from the living body. In order to prevent permeation into the body, it is preferable to selectively permeate ions of the opposite polarity to the medicinal ions of the target drug.
- the electrolyte-containing portion 9 in the counter electrode structure 2 is obtained by dissolving an ionic electrolyte in a solvent such as water or ethanol, or by mixing the solution with polyvinyl alcohol / polyvinyl pyrrolidone. Gels or those obtained by impregnating a porous film, gauze, or the like with the solution or the like can be used.
- the ionic electrolyte can be used without any limitation as long as it is ionic when dissolved in a solvent such as water or ethanol such as sodium chloride or potassium chloride.
- an ion exchange membrane may be further provided between the counter electrode 4 ′ and the ion exchange membrane 10.
- a sheet made of ion-conductive gel, porous film, woven cloth, or the like through which ions can pass.
- a porous film or woven fabric impregnated with an ionic conductive gel or an ionic electrolyte solution, or an ionic electrolyte solution, may be provided between the ion-exchange membrane and the closest ion exchange membrane.
- the power supply unit 3 in the iontophoresis device of the present invention includes a c- working electrode structure 1, a counter electrode structure 2, and a power supply unit used in a normal iontophoresis device, which can be used without any limitation. If the power supply unit 3 is independent, an external power supply that can be connected to a battery or a system power supply can be used. In this case, a power supply such as a voltage or current stabilization system or a system for applying a pulse current is used. It is preferable to have a control system.
- the iontophoresis device of the present invention When the iontophoresis device of the present invention is portable, it is preferable to use a battery as a power source.
- the battery include a coin-type silver oxide battery, an air zinc battery, and a lithium ion battery.
- the working electrode structure 1, the counter electrode structure 2, and the power supply unit 3 are incorporated in a single exterior material, making it small and portable. It can be an event phoresis device.
- a portable iontophoresis device when such a portable iontophoresis device is used, it is more preferable to use a highly flexible resin or rubber as an exterior material, since high followability to the skin shape can be obtained.
- the method of using the apparatus for iontophoresis of the present invention is not particularly limited, and may be used according to a known method.
- the working electrode structure 1 and the counter electrode structure 2 are used for drug penetration. It is only necessary to bring the battery into close contact with a certain living body surface, and then apply a voltage from the power supply unit 3 to flow a current.
- the ion exchange membrane 6 in the working electrode structure 1 so as to be located between the drug containing portion 5 and the surface of the living body, the pharmacological effect generated from the ionic drug present in the drug containing portion 6 can be reduced.
- the ions have permeate the living body through the ion exchange membrane 6.
- the iontophoresis device of the present invention using the ion exchange membrane 6 having such a porous film as a base material has various effects of the conventional iontophoresis device using the ion exchange membrane,
- the dose of the target drug can be extremely high. Furthermore, since the dose is large, it is easy to reduce the size, and it is less likely to peel off or break the ion-exchange membrane even when it is moved with the device attached. It is particularly effective as a cis device. Examples In order to more specifically describe the present invention, examples and comparative examples will be described below, but the present invention is not limited to these examples.
- the characteristics of the ion-exchange membranes shown in the examples and comparative examples indicate values measured by the following methods.
- the hydrogen ion type is replaced with a sodium ion type with a 1 (mol ZI) NaCI aqueous solution, and the liberated hydrogen ions are potentiometrically titrated with a sodium hydroxide aqueous solution.
- a cation exchange membrane the hydrogen ion type is replaced with a sodium ion type with a 1 (mol ZI) NaCI aqueous solution, and the liberated hydrogen ions are potentiometrically titrated with a sodium hydroxide aqueous solution.
- the chloride ion exchange resin is replaced with a nitrate ion exchange resin with a 1 (mo I / I) NaNO 3 aqueous solution, and the released chloride ions are converted into an aqueous silver nitrate solution. It was quantified using a potentiometric titrator (COM TITE-900, manufactured by Hiranuma Sangyo Co., Ltd.) (Amo I).
- the same ion-exchange membrane is immersed in 1 (mol ZI) NaCI aqueous solution for 4 hours or more, washed thoroughly with ion-exchanged water, taken out of the membrane, wiped off the surface moisture with tissue paper, etc. (Wg) was measured.
- the membrane was dried under reduced pressure at 60 ° C. for 5 hours, and its weight was measured (D g). Based on the above measured values, the ion exchange capacity was determined by the following equation.
- Ion exchange capacity A X 100 OZW [mmo I — dry weight]
- An ion-exchange membrane is sandwiched in a two-chamber cell with platinum black electrodes, and both sides of the ion-exchange membrane are filled with 3 (mo IXI) sulfuric acid aqueous solution.
- the resistance was measured and determined by the difference between the resistance between the electrodes and the resistance between the electrodes when no ion exchange membrane was provided.
- the membrane used for the above measurement was previously equilibrated in an aqueous solution of 3 (mo 1 -1) sulfuric acid.
- the surface roughness of the surface of the ion-exchange membrane was measured using a three-dimensional roughness measuring instrument (Kosaka Laboratory TDF-3A type).
- the surface roughness Ra of the ion exchange membrane was defined as the ten-point average roughness (Rz) measured with the evaluation length set to 11 mm.
- the dried ion-exchange membrane was placed in an atmosphere at 25 ° C and a relative humidity of 60 ⁇ for at least 1 ⁇ to adjust the humidity. From this, a sample having a width of 30 mm and a length of 20 cm was cut out, and then Clark stiffness was measured in accordance with JIS-P 8143. A smaller value indicates that the ion exchange membrane is more flexible.
- the 0.9% by weight aqueous sodium chloride solution and the two electrode chambers were filled with 0.1 (mol ZI) aqueous sodium lactate solution.
- the ion exchange membrane to be measured is a cation exchange membrane
- the anion exchange membrane obtained in Production Example 1 described later is used as the protective ion exchange membrane.
- the cation exchange membrane obtained in Production Example 7 described later was used.
- the cell was kept at 25 ° C, the chemical solution chamber and the virtual skin chamber were agitated, and a current was applied for 1 hour at a predetermined constant current density or constant voltage.
- the liquid in the virtual skin chamber was withdrawn, and the amount of the drug was measured by liquid chromatography. The same operation was performed without energization, the blank value was measured, and the difference from the amount of drug when energized was calculated to obtain the drug permeation amount.
- Chloromethylstyrene 3 8 0 g, divinylbenzene 2 0 g, t-butyl peroxide O key a monomer composition comprising the shell Chi Le from hexanoate 2 0 g, the monomer composition 4 2 0 g Place in a 50 Om I glass container and place it on a 20 cm x 20 cm porous film (made of polyethylene with a weight average molecular weight of 250,000, film thickness 25 m, average pore diameter 0 0 0 3 ⁇ m,
- the porosity of 370 / o was immersed at 25 ° C. for 10 minutes under atmospheric pressure, and the porous film was impregnated with the monomer composition. Then, taking out the porous film from the monomer composition, 1 0 0 After coating both sides of the porous film with a polyester film of m, 3 kg / cm 2 of nitrogen pressure, 8 0 ° Polymerization was performed by heating at C for 5 hours. Then, the obtained film was reacted at room temperature for 5 hours in an amination bath consisting of 30 parts by weight of 30 parts by weight of trimethylamine, 5 parts by weight of water, and 5 parts by weight of acetone, and then reacted with quaternary ammonium anion. I got the money. The ion exchange capacity, water content, fixed ion concentration, membrane resistance, film thickness, surface roughness, burst strength, and flexibility of the obtained anion exchange membrane were measured. Table 1 shows the results. Production Examples 2-5:
- the porous film was impregnated in the same manner as in Production Example 1, and then the porous film was taken out of the monomer composition, and a polyester film having a thickness of 100 ⁇ m was obtained.
- polymerization was carried out by heating at 45 ° C. for 3 hours and at 75 ° C. for 5 hours under a nitrogen pressure of 3 kg / cm 2 .
- the obtained film was immersed in a mixture of methyl iodide and n-hexane at a ratio of 1: 3 (weight ratio) at 30 ° C. for 24 hours to obtain a quaternary pyridinium-type anion.
- Table 1 shows the results of measuring the ion exchange capacity, water content, fixed ion concentration, membrane resistance, film thickness, surface roughness, and flexibility of the obtained anion exchange membrane.
- the monomer composition shown in Table 1 was filled in a porous film in the same manner as in Production Example 1. Subsequently, the porous fill ⁇ the out taken from the monomer composition, 1 0 0 After coating both sides of the porous film with a polyester film of m, 3 kg Z cm 2 of nitrogen pressure, 8 0 Polymerization was performed by heating at ° C for 5 hours. Next, the obtained film was immersed in a 1: 1 mixture of 98% concentrated sulfuric acid and a cuprosulfonic acid having a purity of 900/0 or more at 40 ° C for 45 minutes to obtain a sulfonic acid-type cation exchange product. I got it. The ion exchange capacity, water content, fixed ion concentration, fluge resistance, film thickness, surface roughness and flexibility of the obtained cation exchange membrane were measured. The results are shown in Table 1.
- Neosepta AMX manufactured by Tokuyama; membrane properties are listed in Table 1.
- the drug permeation amount through the virtual skin system was measured in the same manner as in Example 1.
- Table 2 shows Yuto.
- the drug permeation amount was measured in the same manner as in Example 1 using only the virtual skin without using the ion exchange membrane to be measured. Table 2 shows the results.
- the drug permeation amount was measured in the same manner as in Example 7 using only the virtual skin without using the ion exchange membrane to be measured. Table 3 shows the results.
- the drug permeation amount in the living skin system was measured under a constant current condition of a current density of 0.5 mAZcm 2 .
- Shaved rabbit skin (male) was used as living skin.
- Table 8 shows the results of the ion exchange used and the amount of drug permeated.
- the drug permeation amount in the living skin system was measured in the same manner as in Example 13 except that the back skin of a miniature pig (Yucatan Mi crop ig, 5 months old, female) was used as the living skin.
- Table 10 shows the results of the ion exchange membrane used and the amount of drug permeation.
- the iontophoresis device of the present invention uses an ion-exchange membrane based on a porous film, so that the drug can be administered at a higher dose than an ion-exchange membrane conventionally used in iontophoresis. You can achieve the quantity.
- the ion exchange membrane for iontophoresis of the present invention can be formed into a flexible membrane while maintaining the required strength, the ion exchange membrane has excellent followability to skin irregularities, expansion, contraction, and bending. Things. It is presumed that the use of a porous film as the base material allows the thinning to be achieved while maintaining the strength, and the relatively low resin filling amount in the base material. Furthermore, the ion-exchange membrane of the present invention has a feature that, when a battery is used as a power source, the dose can be particularly increased because the membrane can be formed into a membrane having extremely low resistance by thinning. From the above points, the iontophoresis device using the ion exchange membrane of the present invention is particularly useful in a portable device.
- the iontophoresis device of the present invention exerts excellent effects in all applications for which application of iontophoresis has been considered up to now, such as beauty applications, medical applications, and health promotion applications for administering supplements. To be extremely practical for a wider range of applications in order to make the equipment portable.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/536,398 US7734339B2 (en) | 2002-11-27 | 2003-11-26 | Iontophoresis apparatus |
EP03811932A EP1566197A4 (en) | 2002-11-27 | 2003-11-26 | Iontophoresis device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002343158 | 2002-11-27 | ||
JP2002-343158 | 2002-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004047916A1 true WO2004047916A1 (ja) | 2004-06-10 |
Family
ID=32375914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015105 WO2004047916A1 (ja) | 2002-11-27 | 2003-11-26 | イオントフォレーシス装置 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7734339B2 (ja) |
EP (1) | EP1566197A4 (ja) |
WO (1) | WO2004047916A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1649891A1 (en) * | 2004-10-21 | 2006-04-26 | Tokuyama Corporation | Working electrode assembly for iontophoresis and iontophoresis device |
RU2394609C2 (ru) * | 2005-02-03 | 2010-07-20 | Тти Эльбо, Инк. | Ионтофоретический аппарат |
RU2409397C2 (ru) * | 2006-08-30 | 2011-01-20 | ТиТиАй Эллебо, Инк. | Устройство для ионтофореза |
US11040190B2 (en) | 2011-07-18 | 2021-06-22 | Djo, Llc | Electrodes, electrode systems, and methods of manufacture |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3493359B1 (ja) * | 2003-03-20 | 2004-02-03 | 宣美 辛島 | イオン泳動式治療装置 |
US7706873B2 (en) * | 2004-05-05 | 2010-04-27 | Mario Ammirati | System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue |
JP2005334339A (ja) * | 2004-05-27 | 2005-12-08 | Tokuyama Corp | イオントフォレーシス用イオン交換膜の製造方法 |
US7590444B2 (en) | 2004-12-09 | 2009-09-15 | Tti Ellebeau, Inc. | Iontophoresis device |
US8295922B2 (en) | 2005-08-08 | 2012-10-23 | Tti Ellebeau, Inc. | Iontophoresis device |
US8386030B2 (en) | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20100016781A1 (en) * | 2005-08-29 | 2010-01-21 | Mizuo Nakayama | Iontophoresis device selecting drug to be administered on the basis of information form sensor |
WO2007032446A1 (ja) * | 2005-09-15 | 2007-03-22 | Tti Ellebeau, Inc. | ロッド型イオントフォレーシス装置 |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
US7574256B2 (en) | 2005-09-30 | 2009-08-11 | Tti Ellebeau, Inc. | Iontophoretic device and method of delivery of active agents to biological interface |
JP2009522011A (ja) | 2005-12-30 | 2009-06-11 | Tti・エルビュー株式会社 | 活性物質を生体界面に送達するイオントフォレーシスシステム、装置及び方法 |
CN101495105A (zh) * | 2006-07-05 | 2009-07-29 | Tti优而美株式会社 | 具有自组装树枝状聚合物的输送装置及其使用方法 |
CA2671069A1 (en) | 2006-12-01 | 2008-06-12 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
WO2008082558A2 (en) * | 2006-12-20 | 2008-07-10 | Alza Corporation | Anode for electrotransport of cationic drug |
US20090105634A1 (en) * | 2007-10-17 | 2009-04-23 | Alza Corporation | Anodic Reservoir for Electrotransport of Cationic Drug |
US20090105632A1 (en) * | 2007-10-18 | 2009-04-23 | Padmanabhan Rama V | Electrotransport Of Lisuride |
US9610440B2 (en) * | 2013-06-10 | 2017-04-04 | Iontera, Inc | Systems, devices, and methods for transdermal delivery |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0394771A (ja) | 1989-09-08 | 1991-04-19 | Advance Co Ltd | イオントフォレーゼ用インタフェース |
JPH03504343A (ja) | 1988-10-28 | 1991-09-26 | アルザ コーポレーション | イオントフォレーゼ電極 |
JPH04297277A (ja) | 1991-03-27 | 1992-10-21 | Sogo Biyou Ikagaku Kenkyusho:Kk | 電気泳動による薬剤浸透装置 |
JPH09108362A (ja) * | 1995-10-17 | 1997-04-28 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス電極 |
JPH09201420A (ja) * | 1996-01-30 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | 用時活性型イオントフォレーシス用デバイス |
JPH11239621A (ja) * | 1998-02-25 | 1999-09-07 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス装置 |
JP2000229128A (ja) | 1999-02-10 | 2000-08-22 | R & R Ventures Kk | イオントフォレーゼ装置 |
US20020134687A1 (en) * | 2001-03-23 | 2002-09-26 | Permelec Electrode Ltd., And Katayama Chemical, Inc. | Electrolytic cell and process for the production of hydrogen peroxide solution and hypochlorous acid |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0610277B2 (ja) | 1987-09-28 | 1994-02-09 | ジャパンゴアテックス株式会社 | 膜状素材 |
JP2643459B2 (ja) | 1989-07-06 | 1997-08-20 | 三菱電機株式会社 | パワーデバイスの駆動・保護回路 |
US5082472A (en) | 1990-11-05 | 1992-01-21 | Mallouk Robert S | Composite membrane for facilitated transport processes |
US5246417A (en) * | 1991-12-11 | 1993-09-21 | Alza Corporation | Indicator for iontophoresis system |
BR9302945A (pt) | 1993-07-21 | 1995-03-01 | Johnson & Johnson | Dispositivo para a separação seletiva de cerdas de uma escova de dentes e dispositivo para o corte seletivo de cerdas de uma escova de dentes |
US5503632A (en) * | 1994-04-08 | 1996-04-02 | Alza Corporation | Electrotransport device having improved cathodic electrode assembly |
USRE37307E1 (en) * | 1994-11-14 | 2001-08-07 | W. L. Gore & Associates, Inc. | Ultra-thin integral composite membrane |
WO1997012644A1 (en) * | 1995-09-29 | 1997-04-10 | Becton Dickinson And Company | Improved iontophoretic reservoir apparatus |
JP3417186B2 (ja) | 1996-02-06 | 2003-06-16 | ソニー株式会社 | 記録再生装置 |
US5941843A (en) * | 1996-07-12 | 1999-08-24 | Empi, Inc. | Iontophoresis electrode |
EP0950407B1 (en) * | 1998-04-14 | 2002-09-04 | Hisamitsu Pharmaceutical Co., Inc. | The use of a GP IIb/IIIa antagonist for the manufacture of a medicament suitable for transdermal application by iontophoresis |
JP2002338721A (ja) | 2001-05-16 | 2002-11-27 | Asahi Kasei Corp | ポリオレフィン樹脂多孔質フィルム |
US20030134687A1 (en) * | 2002-01-11 | 2003-07-17 | Truesdale Gary N. | Multi-use golf club head |
-
2003
- 2003-11-26 EP EP03811932A patent/EP1566197A4/en not_active Withdrawn
- 2003-11-26 US US10/536,398 patent/US7734339B2/en not_active Expired - Fee Related
- 2003-11-26 WO PCT/JP2003/015105 patent/WO2004047916A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03504343A (ja) | 1988-10-28 | 1991-09-26 | アルザ コーポレーション | イオントフォレーゼ電極 |
JPH0394771A (ja) | 1989-09-08 | 1991-04-19 | Advance Co Ltd | イオントフォレーゼ用インタフェース |
JPH04297277A (ja) | 1991-03-27 | 1992-10-21 | Sogo Biyou Ikagaku Kenkyusho:Kk | 電気泳動による薬剤浸透装置 |
JPH09108362A (ja) * | 1995-10-17 | 1997-04-28 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス電極 |
JPH09201420A (ja) * | 1996-01-30 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | 用時活性型イオントフォレーシス用デバイス |
JPH11239621A (ja) * | 1998-02-25 | 1999-09-07 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス装置 |
JP2000229128A (ja) | 1999-02-10 | 2000-08-22 | R & R Ventures Kk | イオントフォレーゼ装置 |
US20020134687A1 (en) * | 2001-03-23 | 2002-09-26 | Permelec Electrode Ltd., And Katayama Chemical, Inc. | Electrolytic cell and process for the production of hydrogen peroxide solution and hypochlorous acid |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1649891A1 (en) * | 2004-10-21 | 2006-04-26 | Tokuyama Corporation | Working electrode assembly for iontophoresis and iontophoresis device |
RU2394609C2 (ru) * | 2005-02-03 | 2010-07-20 | Тти Эльбо, Инк. | Ионтофоретический аппарат |
RU2409397C2 (ru) * | 2006-08-30 | 2011-01-20 | ТиТиАй Эллебо, Инк. | Устройство для ионтофореза |
US11040190B2 (en) | 2011-07-18 | 2021-06-22 | Djo, Llc | Electrodes, electrode systems, and methods of manufacture |
Also Published As
Publication number | Publication date |
---|---|
EP1566197A4 (en) | 2008-07-09 |
US7734339B2 (en) | 2010-06-08 |
US20060241548A1 (en) | 2006-10-26 |
EP1566197A1 (en) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004047916A1 (ja) | イオントフォレーシス装置 | |
JP2004188188A (ja) | イオントフォレーシス用装置 | |
JP4731931B2 (ja) | イオントフォレーシス装置 | |
EP1649891B1 (en) | Working electrode assembly for iontophoresis and iontophoresis device | |
US7479132B2 (en) | Patch material for ionic medicine administration | |
US20060129085A1 (en) | Iontophoresis device | |
MXPA04004153A (es) | Equipo de iontoforesis. | |
WO2007023907A1 (ja) | 冷凍型イオントフォレーシス用電極構造体 | |
KR20080003814A (ko) | 외용제, 외용제의 도포방법, 이온토포레시스장치, 및경피패치 | |
WO2007026671A1 (ja) | センサからの情報により投与すべき薬剤の選定を行うイオントフォレーシス装置 | |
WO2007037324A1 (ja) | 乾燥型イオントフォレーシス用電極構造体 | |
WO2005115534A1 (ja) | イオントフォレーシス装置 | |
EP1844813B1 (en) | Iontophoresis apparatus | |
EP1820533B1 (en) | Ion-tophoretic apparatus | |
JP4606118B2 (ja) | イオントフォレーシス装置用作用極構造体の製造方法 | |
JP4606117B2 (ja) | イオントフォレーシス用作用極構造体及びイオントフォレーシス用装置 | |
US20090124957A1 (en) | Method of Producing an Ion-Exchange for Iontophoresis | |
HK1112725A (en) | Iontophoresis apparatus | |
WO2007043605A1 (ja) | 粘膜付着型イオントフォレーシス装置 | |
KR20170004678A (ko) | 히알루론산을 포함하는 이온토포레시스 장치 및 그를 사용하여 히알루론산을 전달하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003811932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003811932 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006241548 Country of ref document: US Ref document number: 10536398 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10536398 Country of ref document: US |